Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy

Yicong Chen,Huijiao Chen,Ruixuan Yu,Xiaoxiao Zeng,Dong Tian,Qiang Pu,Yongmei Liu
DOI: https://doi.org/10.1016/j.lungcan.2024.107476
IF: 6.081
2024-01-25
Lung Cancer
Abstract:Pulmonary blastomas (PB) are an extremely rare type of lung cancer. Currently, no standard treatment exists for PB. Immunotherapy with checkpoint inhibitors and anti-angiogenesis treatments has been an effective method for lung cancer; however, studies on PB treatment are lacking. Herein, we present a case report of successful conversion therapy with immunotherapy and targeted therapy for PB. After receiving treatment with a PD-1 inhibitor (penpulimab) and a multi-target tyrosine kinase inhibitor (anlotinib) treatment, the patient showed an impressive response and underwent a successful operation. We also summarized and reviewed literature reports on PubMed from January 1, 2000, to December 31, 2022, using the keyword "pulmonary blastoma", discussing the efficacy and specifics of chemotherapy and radiotherapy. Immunotherapy, in combination with targeted therapy, should be considered a potential therapeutic strategy for PB.
oncology,respiratory system
What problem does this paper attempt to address?